New obesity drug shows promise in early trial
NCT ID NCT06313528
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 19 times
Summary
This early-stage study tested an experimental drug called LY3437943 in 85 adults with obesity. The goal was to see how the drug affects calorie intake, energy burned, and appetite compared to a placebo. Participants were followed for up to 6 months, and the results will help guide future research on weight management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Orlando
Orlando, Florida, 32804, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808, United States
Conditions
Explore the condition pages connected to this study.